Biomedicines,
Journal Year:
2023,
Volume and Issue:
11(3), P. 952 - 952
Published: March 20, 2023
As
pharmacology
and
science
progress,
we
discover
new
generations
of
medicines.
This
relationship
is
a
response
to
the
increasing
demand
for
medicaments
powered
by
progress
in
medicine
research
about
respective
entities.
However,
have
questions
efficiency
pharmacotherapy
individual
groups
patients.
The
effectiveness
therapy
controlled
many
variables,
such
as
genetic
predisposition,
age,
sex
diet.
Therefore,
must
also
pay
attention
microbiota,
which
fulfill
lot
functions
human
body.
Drugs
used
psychiatry,
gastroenterology,
diabetology
other
fields
been
demonstrated
possess
much
potential
change
composition
probably
function
intestinal
consequently
creates
long-term
risks
developing
chronic
diseases.
article
describes
amazing
interactions
between
gut
microbes
drugs
currently
healthcare.
Journal of Xenobiotics,
Journal Year:
2023,
Volume and Issue:
13(3), P. 386 - 401
Published: July 25, 2023
The
psychedelic
renaissance
has
reignited
interest
in
the
therapeutic
potential
of
psychedelics
for
mental
health
and
well-being.
An
emerging
area
is
modulation
effects
by
gut
microbiome—the
ecosystem
microorganisms
our
digestive
tract.
This
review
explores
intersection
microbiome
therapy,
underlining
implications
personalized
medicine
health.
We
delve
into
current
understanding
gut–brain
axis,
its
influence
on
mood,
cognition,
behavior,
how
may
affect
metabolism
bioavailability
substances.
also
discuss
role
variations
shaping
individual
responses
to
psychedelics,
along
with
risks
benefits.
Moreover,
we
consider
prospect
microbiome-targeted
interventions
as
a
fresh
approach
boost
or
modulate
therapy’s
effectiveness.
By
integrating
insights
from
fields
psychopharmacology,
microbiology,
neuroscience,
objective
advance
knowledge
about
intricate
relationship
between
substances,
thereby
paving
way
novel
strategies
optimize
outcomes
amid
ongoing
renaissance.
Gut Microbes,
Journal Year:
2023,
Volume and Issue:
15(2)
Published: Nov. 20, 2023
Intestinal
bacteria
are
equipped
with
an
enzyme
apparatus
that
is
involved
in
the
active
biotransformation
of
xenobiotics,
including
drugs.
Pharmacomicrobiomics,
a
new
area
pharmacology,
analyses
interactions
between
and
xenobiotics.
However,
there
another
side
to
coin.
Pharmacotherapeutic
agents
can
significantly
modify
microbiota,
which
consequently
affects
their
efficacy.
In
this
review,
we
comprehensively
gathered
scientific
evidence
on
interplay
anticancer
therapies
gut
microbes.
We
also
underlined
how
such
might
impact
host
response
given
therapy.
discuss
possibility
modulating
microbiota
increase
effectiveness/decrease
incidence
adverse
events
during
tumor
The
anticipation
future
brings
target
interest
efficacy
Healthcare,
Journal Year:
2024,
Volume and Issue:
12(2), P. 226 - 226
Published: Jan. 16, 2024
Background:
Pediatric
autoimmune
neuropsychiatric
disorders
associated
with
streptococcal
(strep)
infections
(PANDAS)
are
a
recognized
medical
entity
among
children.
But
evidence
for
strep-mediated
sudden-onset
obsessive–compulsive
disorder
(OCD)
in
young
adults
is
very
limited.
Delayed
strep
assessment
and
treatment
may
negatively
impact
clinical
outcomes.
Methods:
We
describe
adult
acute
OCD
(age
24),
treated
unsuccessfully
medication
therapy
3
years.
At
age
27,
antistreptolysin-O
(ASO)
was
tested,
based
on
extensive
pediatric
history
of
infections.
Antibiotic
initiated.
Results:
Magnetic
resonance
imaging
(MRI)
identified
new
temporal
lobe
hyperintensity
at
onset
which
persisted
ages
25
30.
ASO
titers
were
elevated
from
27
through
29.
Following
Amoxicillin
treatment,
initially
increased.
Subsequent
+
Clavulin
produced
improved
symptoms
response,
no
adverse
effects.
Conclusion:
These
results
strongly
suggest
an
association
infection,
neuro-inflammation
this
whose
response
to
successful
only
after
high-dose
antibiotic
intervention.
Greater
remission
potential
be
possible
earlier
identification
than
years
post
onset.
findings
add
the
limited
literature
as
etiology
adults.
They
also
lend
urgency
increased
frontline
awareness
early
The
psychedelic
renaissance
has
reignited
interest
in
the
therapeutic
potential
of
psychedelics
for
mental
health
and
well-being.
An
emerging
area
is
modulation
effects
by
gut
microbiome
-
ecosystem
microorganisms
residing
our
digestive
tract.
This
review
explores
intersection
therapy,
underlining
implications
personalized
medicine
health.
We
delve
into
current
understanding
gut-brain
axis,
its
influence
on
mood,
cognition,
behavior,
how
may
affect
metabolism
bioavailability
substances.
also
discuss
role
variations
shaping
individual
responses
to
psychedelics,
along
with
risks
benefits.
Moreover,
we
consider
prospect
microbiome-targeted
interventions
as
a
fresh
approach
boost
or
modulate
therapy's
effectiveness.
By
synthesizing
insights
from
fields
psychopharmacology,
microbiology,
neuroscience,
objective
advance
knowledge
about
intricate
relationship
between
substances,
thereby
paving
way
novel
strategies
optimize
outcomes
amid
ongoing
renaissance.
